Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline

Argenx has entered into a definitive agreement to acquire Forte Biosciences in a deal valued at $2.2 billion. This strategic acquisition aims to strengthen the autoimmune drug pipeline of Argenx through the addition of a differentiated immune drug. Following the announcement of the takeover agreement, shares of Forte Biosciences experienced a significant jump. The transaction focuses on enhancing therapeutic capabilities within the immune sector by integrating the specialized assets held by Forte Biosciences.